BACKGROUND: We investigated pretreatment fasting glucose as a predictor of patients' important outcomes in breast and colorectal cancers undergoing targeted therapies. PATIENTS AND METHODS: In a historic cohort of 202 breast and 218 colorectal cancers treated with targeted agents from 1998 to 2009, we used the Kaplan-Meier method and the log-rank test to estimate survival through tertiles of fasting glucose and the Cox proportional hazards model for multivariate analysis stratified by primary site of cancer and including gender, age and body mass index. RESULTS: The median follow-up was 20 months (1-128). At 60 months, 65% of patients in the lowest tertile of fasting glucose did not experiment disease progression compared with 34% in the highest tertile (P=0.001). Seventy-six percent of females in the lowest tertile showed no progression compared with 49% in the top tertiles (P=0.015). In multivariate analysis, fasting glucose was a significant predictor of time to disease progression only in breast cancer patients in the first tertile compared with the third (P=0.017). CONCLUSIONS: We found evidence of a predictive role of pretreatment fasting glucose in the development of resistance in breast cancer patients treated with targeted agents. Prospective studies are warranted to confirm our findings.
BACKGROUND: We investigated pretreatment fasting glucose as a predictor of patients' important outcomes in breast and colorectal cancers undergoing targeted therapies. PATIENTS AND METHODS: In a historic cohort of 202 breast and 218 colorectal cancers treated with targeted agents from 1998 to 2009, we used the Kaplan-Meier method and the log-rank test to estimate survival through tertiles of fasting glucose and the Cox proportional hazards model for multivariate analysis stratified by primary site of cancer and including gender, age and body mass index. RESULTS: The median follow-up was 20 months (1-128). At 60 months, 65% of patients in the lowest tertile of fasting glucose did not experiment disease progression compared with 34% in the highest tertile (P=0.001). Seventy-six percent of females in the lowest tertile showed no progression compared with 49% in the top tertiles (P=0.015). In multivariate analysis, fasting glucose was a significant predictor of time to disease progression only in breast cancerpatients in the first tertile compared with the third (P=0.017). CONCLUSIONS: We found evidence of a predictive role of pretreatment fasting glucose in the development of resistance in breast cancerpatients treated with targeted agents. Prospective studies are warranted to confirm our findings.
Authors: Laura A Colangelo; Susan M Gapstur; Peter H Gann; Alan R Dyer; Kiang Liu Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-04 Impact factor: 4.254
Authors: Degeng Wang; Sandip Patil; Wenhui Li; Lisa E Humphrey; Michael G Brattain; Gillian M Howell Journal: Oncogene Date: 2002-04-25 Impact factor: 9.867
Authors: Sharon H Saydah; Elizabeth A Platz; Nader Rifai; Michael N Pollak; Frederick L Brancati; Kathy J Helzlsouer Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-05 Impact factor: 4.254
Authors: J L Wright; S R Plymate; M P Porter; J L Gore; D W Lin; E Hu; S B Zeliadt Journal: Prostate Cancer Prostatic Dis Date: 2013-03-05 Impact factor: 5.554
Authors: Alice P S Kong; Xilin Yang; Wing-Yee So; Andrea Luk; Ronald C W Ma; Risa Ozaki; Kitty K T Cheung; Heung-Man Lee; Linda Yu; Gang Xu; Chun-Chung Chow; Juliana C N Chan Journal: BMC Med Date: 2014-05-13 Impact factor: 8.775